

| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |

Please complete application in full, sign and date, then fax to: 877-427-7290

Or email to: ViatrisPAP@viatris.com

- The PAP Application must be complete to be reviewed for patient program eligibility. Please ensure all areas of the form are completed in full, including all signatures.
- To be considered for the Viatris Patient Assistance Program, all applicants must satisfy the following requirements and eligibility criteria:
 - Applicants qualify for the program financial requirements.
 - Applicants must be a current United States resident (includes U.S Territories).
 - Applicant must be fully uninsured or if insured, have no prescription drug insurance.
 - The requested product must be prescribed by a licensed U.S. healthcare professional for a Food and Drug Administration (FDA) approved indication.
- Each applicant will be individually assessed for program eligibility based on the information provided within this application.
- Applicants will only be evaluated for eligibility upon receipt of a completed and signed Viatris Patient Assistance Program (PAP) Application.





| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |

Patient Information			
Name		Date of Birth: / /	SCNI
Name: Last Address*	City	Mo Day	Year (Required)
Home Phone: Cell Ph			
Preferred Contact: Cell Phone Home Pho			
Insurance: Uninsured Commercial			: 🗌 Yes 🗌 No
Insurance Name:		-	*No PO Boxes Accepted
Prescriber Information			
Prescriber Name:		Prescriber NPI	:
Facility Name:		State License	#:
Facility Address:	City:		State: ZIP:
Primary Office Contact:			
Phone Number:			
Prescriber Shipping Address (Only	complete if shipping addres	s is different than addres	s listed above)
Droopriker Neme		Facility Norma	
Prescriber Name:			
Shipping Address:	City:		State: ZIP:
Shipment Contact Name:			
Phone Number:	Contact Email:		





| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |

Ohio Prescriber Mandatory Subsection (Select an option below, complete the related fields, then sign & date)	
MANDATORY SUBSECTION FOR ALL OHIO HCPs	
Under Ohio law, a licensed manufacturer, outsourcing facility, third-party logistics provider, repackager, or wholesale distributor, may only pro- prescription drugs to a prescriber whose practice is licensed as a Terminal Distributor of Dangerous Drugs ("TDDD") or is exempt from such licensure under Ohio Revised Code ("ORC") § 4729.541. A TDDD license allows a business entity to receive, purchase, and possess prescript drugs, including drug samples, for distribution to patients. For more information on TDDD licensing requirements for prescribers, please visit th Ohio Board of Pharmacy website at www.pharmacy.ohio.gov/PrescriberTDDD, and for a list of exemptions, please refer to section 4729.541 o ORC. The above information is being provided for your convenience and is not offered, nor should it be construed, as legal advice.	ption he
Please select and complete one of the following and sign below:	
The shipping address I provided above for the following practice, has an active TDDD license that	ıt
allows me to receive and store the requested prescription drug products at this location. The TDDD license number is	
-OR-	
The shipping address I provided above for the following practice, is subject to one of the TDDD licensing exemptions in ORC § 4729.541.	
By signing below, I warrant that the information provided above is complete and accurate and attest that I can receive and store the requested prescription drug products at the shipping address I provided because I hold an unrestricted, active TDDD license or my practice is exempt fro obtaining a TDDD license under ORC § 4729.541.	
Prescriber Signature: Date:	
(Original signature -and- date required, stamped signatures not accepted)	





| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8am to 5pm EST |


Arixtra® (fondaparinux sodium) injection, solution
2.5mg/0.5mL PFS 10PK
5mg/0.4mL PFS 10PK
7.5mg/0.6mL PFS 10PK
10mg/0.8mL PFS 10PK
BREYNA® (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol
80mcg/4.5mcg
160mcg/4.5mcg
Cortifoam® (hydrocortisone acetate 10%) rectal foam
10% 15g QTY
Cystagon® (Cysteamine bitartrate) capsules
50mg C 500s
150mg C 500s
Denavir® (penciclovir) Cream
1% 5gm QTY
Dipentum® (olsalazine sodium) capsule
250mg C 100s
Dymista® azelastine hydrochloride & fluticasone propionate) nasal spray
137/50mcg Nasal Spray 23g QTY

EMSAM® Transdermal System
12 mg/24 hr Bx30
6 mg/24 hr Bx30
TDS 9 mg/24 hr Bx30
ERMEZA™ (levothyroxine sodium) oral solution
150 mcg/5mL 150mL
150 mcg/5mL 75mL
Felbatol® (felbamate)
400mg T 100s
600mg T 100s
Gastrocrom® (cromolyn sodium, USP) oral concentrate
100mg 5mL Oral Concentrate 96s
Perforomist® (formoterol fumarate) Inhalation Solution
20 mcg / 2 mL 30x1
20 mcg / 2 mL 60x1
Pretomanid Tablets
200mg T 26
Proctofoam®HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1%)
HC 1% 10g

ROWA	SA® (mesalamine) Rectal Suspension
	60mL Rectal Susp 7s
QTY	
	60mL Rectal Susp 28s
QTY	
sfROW	ASA® (mesalamine) Rectal Suspension
	60mL Rectal Susp 7s
QTY	
	60mL Rectal Susp 28s
QTY	
TYRV	AYA® (varenicline solution) nasal spray
	0.03 mg 2pk
QTY	
Marcal	
	a Inhub® (fluticasone propionate and
	almeterol inhalation powder, USP)
Sá	
	almeterol inhalation powder, USP) 100mcg/50mcg 60/Inh
Sá	almeterol inhalation powder, USP)
QTY	almeterol inhalation powder, USP) 100mcg/50mcg 60/Inh 250mcg/50mcg 60/Inh
QTY QTY	almeterol inhalation powder, USP) 100mcg/50mcg 60/Inh
QTY QTY QTY	almeterol inhalation powder, USP) 100mcg/50mcg 60/Inh 250mcg/50mcg 60/Inh 500mcg/50mcg 60/Inh
QTY QTY QTY	almeterol inhalation powder, USP) 100mcg/50mcg 60/Inh 250mcg/50mcg 60/Inh
QTY QTY QTY	almeterol inhalation powder, USP) 100mcg/50mcg 60/Inh 250mcg/50mcg 60/Inh 500mcg/50mcg 60/Inh E® (norelgestromin and ethinyl estradiol
QTY QTY QTY	almeterol inhalation powder, USP) 100mcg/50mcg 60/Inh 250mcg/50mcg 60/Inh 500mcg/50mcg 60/Inh E® (norelgestromin and ethinyl estradiol transdermal system)
۲۲۲ ۵۲۲ ۵۲۲ ۲۷ ۲۷ ۲۲	almeterol inhalation powder, USP) 100mcg/50mcg 60/Inh 250mcg/50mcg 60/Inh 500mcg/50mcg 60/Inh E® (norelgestromin and ethinyl estradiol transdermal system)
۲۲۲ ۵۲۲ ۵۲۲ ۲۷ ۲۷ ۲۲	almeterol inhalation powder, USP) 100mcg/50mcg 60/Inh 250mcg/50mcg 60/Inh 500mcg/50mcg 60/Inh E® (norelgestromin and ethinyl estradiol transdermal system) TDS 0.15mg/0.035mg/QD 3s



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST



Prescriber Certification and Prescription Signature

I certify that the information provided in this Patient Assistance Program Application is complete and accurate to the best of my knowledge, that the Viatris product I have prescribed to the applicant within this application is based on my professional judgment of medical necessity for a Food and Drug Administration (FDA) approved indication, and that I will supervise the patient's medical treatment. I will notify Viatris PAP immediately if the Viatris product is no longer medically necessary for this patient's treatment. I certify that I have obtained from my patient all required written authorizations for the release of my patient's personal identification and insurance information to Viatris and their agents and representatives.

By signing below, I attest that I can prescribe, receive, store, and dispense the Viatris product and that I, and the facility located at the shipping address I provided above that will receive the product, hold all required state licenses to receive, store, and dispense the product.

I understand that any information provided to Viatris and its agents and representatives is for the sole use of Viatris and their agents, service providers, and representatives to verify my patient's insurance coverage status, to assess the patient's eligibility for participation in the Viatris Patient Assistance Program (collectively, "the Program"), and to otherwise administer the product and related services. I understand that application to the Program does not guarantee that assistance will be obtained.

I understand that Viatris may change or cancel this program at any time. I understand that if my patient's financial and/or insurance status changes, the patient may no longer be eligible for the Program, and I agree to immediately notify a Viatris PAP representative if I become aware of changes in the patient's financial and/or insurance status. I agree that Viatris PAP may contact me for additional information relating to this application either by fax, e-mail and/or telephone. I understand that I am under no obligation to prescribe any Viatris product and that I have not received, nor will I receive, any benefit from Viatris or its agents or representatives for prescribing a Viatris product. I agree that I will not sell, submit claims or make any attempt to receive reimbursement from any third party for any product provided by the Program.

By signing this Patient Assistance Program Application, I authorize the release of medical and/or other patient information to agents and service providers of Viatris to use and disclose as necessary for verification of patient eligibility, and to furnish any information on this form to the insurer of the applicant for the purpose of verifying benefit eligibility. I understand that Program duration per eligibility period is 12 months, and the maximum number of refills per eligible patient is 11 for each unique enrollment.

Prescriber Certification & Prescription Signature:

(original signature required)

_____ Date: _____







| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |

Patient Authorization and Agreement Signature

By signing this Authorization, I authorize each of my physicians, pharmacists, including any non-commercial pharmacy that receives my prescription ("my Prescribed Product"), and other healthcare providers (together "Healthcare Providers") and each of my health insurers, if any (together, "Insurers") to disclose my Protected Health Information, including but not limited to medical records, information related to my medical condition and treatment, my health insurance coverage, my name, address, telephone number, Social Security number, insurance plan and or group numbers (together, "Protected Health Information") to Viatris, its affiliated companies, vendors, agents, collaboration partners, and representatives (together, "Viatris") including providers of alternate sources of funding for prescription drug costs, and other service providers supporting the Viatris Patient Assistance Program (PAP) (collectively, the "Program") for the purposes described below.

Specifically, I authorize disclosure of my Protected Health Information in order to:

- Ι. Enroll me in, and contact me about the Program, including online support, financial assistance services, and co-pay assistance services, as applicable,
- 11. Communicate with my Healthcare Providers and Insurers about benefits, coverage, and medical care, including compliance with Product treatments,
- III. Facilitate dispensing of my prescription by a non-commercial pharmacy,
- IV. Provide me with educational materials, information and services related to my treatment experience with my prescribed medication and my condition,
- V Verify, investigate, and coordinate with my Insurers regarding my prescribed medication, and
- VI. Contact me as otherwise required or permitted by law.

Once my Protected Health Information has been disclosed to Viatris, I understand that federal privacy laws no longer protect the information. However, Viatris agrees to protect my Protected Health Information by using and disclosing it only for the purposes described in this Authorization or as permitted by law. I understand that I may refuse to sign this Authorization. My choice about whether to sign will not change the way my Healthcare Providers or Insurers treat me, but I will not have access to the Viatris Patient Assistance Program and the services provided by Viatris under the Program. If I refuse to sign the Authorization, or revoke my Authorization later, I understand that this means I will not be able to participate in or receive assistance from the Program.

I understand that my signed Authorization is valid for 5 years from the date of my signature, and that I may revoke this Authorization at any time in the future, except to the extent that actions have been taken in reliance on the Authorization. I understand that to revoke this Authorization I may mail a request to 3711 Collins Ferry Road Morgantown, WV 26505, fax to 877-427-7290, or by calling 888-417-5780. I understand that revoking this Authorization will end further uses and disclosure of my Protected Health Information by the parties identified above except to the extent those uses and disclosures have been made in reliance upon this Authorization as permitted by applicable law. I am entitled to receive a copy of this Authorization.

I understand that if I qualify and I am enrolled in the Program sponsored by Viatris, I will receive my Prescribed Product from Viatris only pursuant to a legally valid prescription from my health care provider. I understand that if I qualify and I am enrolled in the Program, Viatris will provide me my Prescribed Product free of charge for the duration of the enrollment period so long as I have a legally valid prescription for my Prescribed Product. I understand that I am not required to continue treatment with my Prescribed Product if I gain insurance coverage, or to receive treatment from any given provider. I understand and agree that I must notify Viatris PAP at 888-417-5780 immediately if my insurance status changes during the Program enrollment period. I understand and agree that neither I nor my Insurers, if applicable, will be charged for the supply of my Prescribed Product that I received from the Program, and that under NO circumstances may I claim reimbursement from my Insurers or any other third party for the Prescribed Product provided to me free of charge from the Program. I understand that Viatris reserves the right at any time without notice to modify or discontinue the Program and its criteria.

I understand that I am providing 'written instructions' to Viatris under the Fair Credit Reporting Act authorizing Experian on behalf of Viatris to obtain information from my credit profile or other information from Experian. I authorize Viatris and its service providers to obtain such information solely for the purpose of determining financial qualifications for the Program. I understand that I must affirmatively agree to the terms in this notice by signing below in order to proceed in the Program financial screening process.

Viatris, Inc. and its affiliates and subsidiaries process your personal data (Name, Contact information, DOB, Social Security number, Gender, Insurance Status, and income) in order to determine whether you qualify for enrollment in the patient assistance program and, if you are enrolled, to administer your participation in the program. You may have the right to report concerns to the authority responsible for data protection where you live or work. You can learn more about our data protection practices in our Viatris Privacy Notice at https://www.viatris.com/en/viatris-privacy-notice, you can learn about the personal data we process, how it is shared, where it is stored, to where it may be transferred, for how long we keep it, and how to contact our Data Protection Officer. For questions or concerns related to data protection, please email dataprivacy@viatris.com.

My signature certifies that I have read and understand the above statements and agree to the outlined terms.

Patient Name (Print): Patient Signature:

Date:





| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |

Patient Authorized Representative

I permit Viatris PAP Support Services representatives to speak with the following person about this application form. This includes discussing the status of my application, insurance and financial questions, any missing documentation and other issues related to my enrollment, or any other treatment- related issues. I may cancel this Patient Authorized Representative Authorization at any time by calling: 888-417-5780

Name of Authorized Representative: ______ Relationship to Patient: ______

Telephone Number: _____ Email: _____

By signing below, I, the patient, allow this representative to speak on my behalf on any matter regarding my enrollment with the Program.

